July 2019
Volume 60, Issue 9
Free
ARVO Annual Meeting Abstract  |   July 2019
Outcomes of cataract surgery in patient with wet age-related macular degeneration while being treated with intravitreal Aflibercept with treat-and-extend regimen.
Author Affiliations & Notes
  • Tatsuya Nagai
    Chiba Univercity Hospital, Chiba, Japan
  • Tomohiro Nizawa
    Chiba Univercity Hospital, Chiba, Japan
  • Masayasu Kitahashi
    Chiba Univercity Hospital, Chiba, Japan
  • Takayuki Baba
    Chiba Univercity Hospital, Chiba, Japan
  • Shuichi Yamamoto
    Chiba Univercity Hospital, Chiba, Japan
  • Takehito Iwase
    Chiba Univercity Hospital, Chiba, Japan
  • Footnotes
    Commercial Relationships   Tatsuya Nagai, None; Tomohiro Nizawa, None; Masayasu Kitahashi, None; Takayuki Baba, None; Shuichi Yamamoto, None; Takehito Iwase, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 88. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Tatsuya Nagai, Tomohiro Nizawa, Masayasu Kitahashi, Takayuki Baba, Shuichi Yamamoto, Takehito Iwase; Outcomes of cataract surgery in patient with wet age-related macular degeneration while being treated with intravitreal Aflibercept with treat-and-extend regimen.. Invest. Ophthalmol. Vis. Sci. 2019;60(9):88.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To determine the best-corrected vision (BCVA) and anatomical changes after cataract surgery in patients with wet age-related macular degeneration (wAMD) who were being treated with intravitreal aflibercept (IVA) with the treat-and-extend regimen (TER).

Methods : All patients who had undergone cataract surgery and were receiving IVA with TER for wAMD at the Chiba University Hospital between February 2015 and February 2017 were studied. There were 18 eyes of 18 patients treated with IVA using TER for 6 months prior to the cataract surgery and had been followed for at least 1 year after the cataract surgery. During the TER, the treatment intervals were sequentially extended or shortened by approximately 2 weeks. The outcome measures were the changes in the BCVA, central retinal thickness (CRT), central choroidal thickness (CCT) relative to that before the surgery, the mean number of injections, the duration of the injections, and the incidence of dry macula at 6 months before, and 6 and 12 months after the cataract surgery.

Results : The mean preoperative period was 2.0±0.7 years (mean±SD), and the mean postoperative follow-up period was 1.7±0.6 years. The mean preoperative number of injections were 17.3±6.7. The mean preoperative BCVA was 1.21±0.57 logMAR units which improved to 0.19 ±0.27 logMAR units at 6 months (P<0.001) and remained at 0.19±0.29 logMAR units at 12 months (P<0.001). The BCVA of all patients was unchanged or was significantly improved at 12 months. The mean CRT and CCT were not significantly changed during the study period. The mean number of injections was 6.9±2.5 during the 12 postoperative months. Six eyes (33%) required a decrease in the interval between injections after the surgery, and 9 eyes (50%) were able to maintain the same interval. Three eyes (17%) had a dry macula at 12 months.

Conclusions : Cataract surgery significantly improves the BCVA of patients with wAMD being treated with IVA with a TER. After cataract surgery, the interval of injections may need to be shortened relative to that before the surgery.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×